TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06731569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advanced intelligence drill
Description: The AI drill is an innovative surgical tool designed specifically for Maxillary Sinus Floor Augmentation (MSFA) procedures. It incorporates advanced technology to enhance safety, precision, and efficiency during lateral window preparation.~It has an Automated Pressure-Sensing Mechanism which makes the drill automatically stops rotating when it detects contact with the Schneiderian membrane, minimizing the risk of perforation.~The OLA kit consists of Hydraulic Lift which is compatibility with the drill connected to a saline-filled syringe to gently elevate the Schneiderian membrane from the sinus floor.~It involves a Multi-Step Drilling Process using different drill tips designed each for a specific task including the pilot drill for initial window creation and the non-cutting ball-end drill for lateral wall thinning and smoothing.~It works at a controlled high-Speed Performance of 6000 RPM with irrigation system included.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rotary instrument
Description: Traditional Rotary Drill~The traditional rotary drill is a commonly used surgical tool in Maxillary Sinus Floor Augmentation (MSFA) procedures, employing conventional drilling techniques for lateral window preparation. It is a widely recognized method due to its accessibility and effectiveness in skilled hands.~It Uses a rose-head bur attached to a surgical straight handpiece that operates at speeds of 800-1200 RPM with irrigation to prevent overheating and ensure efficient bone cutting.~It is a manual operator control that requires the surgeon's skill and experience to control the depth and force of drilling. And relies on visual and tactile feedback to identify when the Schneiderian membrane is close to exposure.~It is versatile and can be adapted to varying bone densities and anatomical complexities. It is effective for creating the window for sinus access.~It comes with an irrigation system to avoid necrosis of the bone.
Study: NCT06730243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retzius-sparing robot-assisted radical prostatectomy and Sandwich Technique of Total Urethral Reconstruction
Description: Retzius-sparing robot-assisted radical prostatectomy and Sandwich Technique of Total Urethral Reconstruction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Robot-Assisted Radical Prostatectomy
Description: Standard Robot-Assisted Radical Prostatectomy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic Radical Prostatectomy
Description: Laparoscopic Radical Prostatectomy
Study: NCT06731816

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck and stabilization exercise group
Description: Participants in this group will attend 2 sessions per week for 8 weeks, for a total of 16 sessions. In addition to neck stretching, range of motion, and isometric exercises applied in the neck exercise group, they will also apply spinal and cervical region stabilization exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck exercise group
Description: Participants in this group will attend 2 sessions per week for 8 weeks, for a total of 16 sessions. They will perform neck stretching, range of motion and isometric exercises.
Study: NCT06729541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multigenetic Pharmacogenomics-Guided Treatment (MPGT)
Description: In the guidance group, drug types and dosages were adjusted based on the results of Pharmacogenetic TESTING.
Study: NCT06730542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib capsules will be self-administered orally by participants at a starting dose of 160 mg twice a day (BID) or 320 mg once a day (QD)\* at the beginning of Cycle 2 of Pola-R-CHP therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants will receive Methotrexate as per standard of care (SOC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants will receive Polatuzumab Vedotin as per standard of care (SOC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive Rituximab as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive Cyclophosphamide as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants will receive Doxorubicin as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive Prednisone as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.
Study: NCT06730646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health effects
Description: Participants in this arm will watch 3 short videos about the smoking-related diseases during the survey data collection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco industry manipulation
Description: Participants in this arm will watch 3 short videos about how the tobacco industry uses targeted marketing and manipulative tactics aimed at youth and young adults during the survey data collection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Secondhand smoke
Description: Participants in this arm will watch 3 short videos about the risks of secondhand smoke exposure during the survey data collection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentral health
Description: Participants in this arm will watch 3 short videos about the effects of smoking on mental health during the survey data collection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social acceptability
Description: Participants in this arm will watch 3 short videos about how smoking is socially unacceptable in China during the survey data collection.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Participants in this arm will watch 3 short videos about drinking bottled water during the survey data collection. These messages display specific water products and describe hydration as a healthy activity.
Study: NCT06731855

Intervention type: PROCEDURE
Intervention: Abdominal Surgery for congenital gut malformation in the first 5 days of life.
Description: Abdominal Surgery for congenital gut malformation in the first 5 days of life. Procedure will depend on the congenital gut malformation.
Study: NCT06731764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Patients will receive Levothyroxine/Placebo~Levothyroxine/Liothyronine with Liothyronine administered twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Patients will receive Levothyroxine/Placebo~Levothyroxine/Liothyronine with Liothyronine administered twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Patients will receive Levothyroxine/Placebo~Levothyroxine/Liothyronine with Liothyronine administered twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine/Liothyronine once daily
Description: Patients will receive Levothyroxine/Liothyronine with Liothyronine administered once daily;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine/Liothyronine twice daily
Description: Patients will receive Levothyroxine/Liothyronine with Liothyronine administered twice daily;
Study: NCT05452421

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isotonic carbohydrate beetroot juice drink
Description: An isotonic carbohydrate beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.2 g carbohydrate per 100 ml. Osmolality 304-310 mOsm/kg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isotonic carbohydrate beetroot juice drink
Description: An isotonic carbohydrate beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.2 g carbohydrate per 100 ml. Osmolality 304-310 mOsm/kg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice drink
Description: A beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.1 g carbohydrate per 100 ml. Osmolality 390-410 mOsm/kg.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice drink
Description: A beetroot juice drink containing 141 mg nitrate per 100 ml (12.9 mmol). Total of 570 ml serving in two doses of 285 ml over one morning. Contains 6.1 g carbohydrate per 100 ml. Osmolality 390-410 mOsm/kg.
Study: NCT06379555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Walanpoigne
Description: Intervention will combine WALANT anesthesia with arthroscopy to reduce a joint fracture of the wrist
Study: NCT06245967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frequency specific microcurrent therapy
Description: Concussion protocol

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Frequency specific microcurrent therapy
Description: Shan concussion protocol
Study: NCT04982016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: crystal therapy
Description: Infusion of 250ml crystal solution before anesthesia induction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: colloid therapy
Description: Infusion of 250ml colloid solution before anesthesia induction
Study: NCT05963828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-hospital management based on WeChat applet
Description: The brain and heart health manager uses the exclusive QR code in the WeChat applet to receive and manage patients. Patients can register and use the WeChat applet by scanning the QR code. The functions of WeChat applet include making medication plan for patients, daily medication reminder, targeted health education, health index monitoring, online consultation and so on.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine post-hospital follow-up management
Description: The brain and mental health managers routinely followed up the patients in the standard group for 1, 3, 6 and 12 months by telephone or outpatient follow-up, the main content of which was to inquire about the medication of patients and the management of stroke risk factors. Targeted health education was carried out according to the risk factors of patients.
Study: NCT05654090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefoperazone sodium and sulbactam sodium
Description: Pharmacokinetic study under fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cefoperazone sodium and sulbactam sodium
Description: Pharmacokinetic study under fasting conditions
Study: NCT04799418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open Label Extension Study
Description: This study will investigate the safety and efficacy of extended treatments for the management of symptoms related to PD.
Study: NCT05603156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the usage of Olverembatinib combined with Inotuzumab Ozogamicin
Description: patients in this arm will accept a 28 days treatment regimen: Olverembatinib 40mg QOD (d1 to d28 )and Inotuzumab Ozogamicin 1.2mg/m2 (divided into 2 days, d1 and d8, 0.6mg/m2, respectively).
Study: NCT05599672

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-targeted Brief Intervention-Medication Therapy Management
Description: Alcohol-targeted Brief Intervention-Medication Therapy Management (ABI-MTM) intervention is a pharmacy-based medication management intervention, combined with Screening, Brief Intervention, and Referral to Treatment. ABI-MTM includes 5 core elements. A common duration for medication counseling in outpatient pharmacies a single 30-45 minute session. These include a medication review, a personal medication record, a medication action plan, a brief motivational intervention, and documentation and follow up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard medication counseling
Description: Standard Medication Counseling (SMC) will be the treatment as usual condition in this study and was chosen/developed following Gold et al.'s guide for selecting control conditions in behavioral intervention studies. For the first component, all SMC participants will receive a single 5-10 minute medication information/counseling session delivered by a pharmacist, other than the study pharmacist, that possesses a similar level of education and professional licensing. The content of this session follows federal and state pharmacy requirements requiring pharmacists to: (1) offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present (not applicable to this study given all patients must screen in person), and (4) discuss generic substitution. Following this session, in the second SMC component, participants will be emailed/mailed (according to participant preference) safety information about co-use of alcohol and opioids.
Study: NCT04866433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real-time binaural sound
Description: Play music with a frequency difference (real-time binaural sound) in each ear through headphones during sedation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Play the same music in both ears through headphones during sedation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Just wear headphones during sedation
Study: NCT05937607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand massage
Description: It is reported in the literature that the application should last 5-10 minutes on average to reduce acute pain, state anxiety, and provide physiological positive changes and relaxation in individuals during the procedure
Study: NCT05004311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: A single oral dose of 0.5 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: A single oral dose of 0.5 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions
Study: NCT04107077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 200mg of Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 30mg of Mitomycin C.
Study: NCT06208800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blend Aromatherapy
Description: Inhalation of a mixture of essential oils of peppermint, palmarosa for 10 minutes at 11:00 am during the day and vetiver, cedar, clary sage, musk sage, grapefruit and petitgrain for 10 minutes at 21:30 pm before bedtime for 4 weeks
Study: NCT05213325

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of serum levels of IL-6 and IL-8
Description: Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits)

Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of serum levels of IL-6 and IL-8
Description: Evaluation of serum levels of IL-6 and IL-8 by Luminex Assay (multiplexed ELISA kits)
Study: NCT04932226

Intervention type: DEVICE
Group type: OTHER
Intervention: cloth mask
Description: Buff bandana double layer worn over nose and mouth

Intervention type: DEVICE
Group type: OTHER
Intervention: surgical mask
Description: standard surgical mask

Intervention type: DEVICE
Group type: OTHER
Intervention: FFP2 respirator
Description: filtering facepiece 2 respirator
Study: NCT05649943

Intervention type: DRUG
Group type: OTHER
Intervention: APA + ADT
Description: All participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily. Apalutamide is distributed in Italy under the trade name of Erleada® 60 mg.~All patients not undergoing surgical castration should also continue medical castration by taking a gonadotropin-releasing hormone (GnRHa) analogue during treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: APA + ADT
Description: All participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily. Apalutamide is distributed in Italy under the trade name of Erleada® 60 mg.~All patients not undergoing surgical castration should also continue medical castration by taking a gonadotropin-releasing hormone (GnRHa) analogue during treatment.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Local Treatmetn RT or RP
Description: Patients who will undergo radiotherapy as a local treatment must be treated according to the following scheme:~External beam radiotherapy administered at 36 Gy in six consecutive weekly fractions of 6 Gy, or 55 Gy in 20 daily fractions of 2・75 Gy over 4 weeks.~Radiation therapy will be given with the patient supine and with a full bladder and an empty rectum. The planned target volume is prostate only, with an 8 mm margin posteriorly and a 10 mm margin elsewhere.~No RT on lymph nodes is foreseen. RT should begin 6 months after the first dose of apalutamide (+/- 2 weeks).~Radical prostatectomy should be performed 6 months after the first dose of apalutamide (+/- 2 weeks).
Study: NCT05207904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab, paclitaxel, Carboplatin
Description: Tislelizumab, 200mg administered intravenously (IV) on Day 1 of each 21-day cycle paclitaxel 175 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6cycle Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6 cycle
Study: NCT06354205

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sliva Procalcitonin
Description: Sliva Procalcitonin vs Blood procalcitonin
Study: NCT04610450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEARO
Description: Robotic system for otological procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTOPLAN
Description: Otological surgical planning software
Study: NCT05071716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD
Description: Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Twice Daily
Study: NCT05106751

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid dermal filler
Description: Hyaluronic acid dermal filler used for facial volume or wrinkle correction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid dermal filler
Description: Hyaluronic acid dermal filler used for facial volume or wrinkle correction
Study: NCT05191368

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06267521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program
Description: Participants will follow daily instructions from the Healthy Minds Program at home for four weeks, including guided meditation exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program
Description: Participants will follow daily instructions from the Healthy Minds Program at home for four weeks, including guided meditation exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program
Description: Participants will follow daily instructions from the Healthy Minds Program at home for four weeks, including guided meditation exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Meditation Didactic Material
Description: Participants will listen to lessons from the Healthy Minds Program at home for four weeks, which will not include any actual meditation exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Stimulation in Lab
Description: On two nights each week during the four weeks of the intervention, participants will sleep in the lab and undergo sham TES-TI stimulation for approximately 10 hours per night

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation in Lab
Description: Participants will sleep in the lab and undergo active TES-TI stimulation for approximately 10 hours per night.
Study: NCT05661253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25 ml of bupivacaine 0.25% via serratus anterior block
Description: patients will receive conventional serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25 ml of bupivacaine 0.25% via modified serratus anterior palne block
Description: patients will receive modified serratus anterior plane block with a volume of 25 ml of bupivacaine 0.25% followed by induction of general anesthesia.
Study: NCT04623359

Intervention type: DEVICE
Group type: OTHER
Intervention: High resolution manometry
Description: High resolution manometry

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High resolution manometry
Description: High resolution manometry
Study: NCT05226247

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Spontaneous breathing trial
Description: To perform cardiac and lung echography before and during a spontaneous breathing trial
Study: NCT04875598

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound assisted - Laparoscopy assisted Transversus Abdominis Plane Block
Description: Ultrasound assisted TAPB application will be applied by an anesthesiology and reanimation specialist and Laparoscopy assisted TAPB application will be applied by the surgeon performing the operation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound assisted - Laparoscopy assisted Transversus Abdominis Plane Block
Description: Ultrasound assisted TAPB application will be applied by an anesthesiology and reanimation specialist and Laparoscopy assisted TAPB application will be applied by the surgeon performing the operation.